Globus Medical (GMED) EBIAT (2016 - 2025)
Globus Medical's EBIAT history spans 15 years, with the latest figure at $140.6 million for Q4 2025.
- For Q4 2025, EBIAT rose 430.44% year-over-year to $140.6 million; the TTM value through Dec 2025 reached $537.9 million, up 422.28%, while the annual FY2025 figure was $537.9 million, 422.28% up from the prior year.
- EBIAT reached $140.6 million in Q4 2025 per GMED's latest filing, up from $119.0 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $202.8 million in Q2 2025 to a low of -$7.1 million in Q1 2024.
- Average EBIAT over 5 years is $55.2 million, with a median of $47.3 million recorded in 2021.
- The largest YoY upside for EBIAT was 5093.99% in 2024 against a maximum downside of 114.49% in 2024.
- A 5-year view of EBIAT shows it stood at $15.1 million in 2021, then soared by 231.42% to $50.1 million in 2022, then plummeted by 69.97% to $15.0 million in 2023, then surged by 76.3% to $26.5 million in 2024, then surged by 430.44% to $140.6 million in 2025.
- Per Business Quant, the three most recent readings for GMED's EBIAT are $140.6 million (Q4 2025), $119.0 million (Q3 2025), and $202.8 million (Q2 2025).